1. Home
  2. STKE vs LGVN Comparison

STKE vs LGVN Comparison

Compare STKE & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STKE

Sol Strategies Inc.

HOLD

Current Price

$1.60

Market Cap

38.3M

Sector

N/A

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.86

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKE
LGVN
Founded
2002
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.3M
34.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
STKE
LGVN
Price
$1.60
$0.86
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
185.8K
665.9K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$552.94
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.85
$0.48
52 Week High
$7.75
$1.80

Technical Indicators

Market Signals
Indicator
STKE
LGVN
Relative Strength Index (RSI) 65.64 39.01
Support Level $1.50 $0.74
Resistance Level $1.65 $0.99
Average True Range (ATR) 0.15 0.06
MACD 0.04 -0.03
Stochastic Oscillator 89.17 2.71

Price Performance

Historical Comparison
STKE
LGVN

About STKE Sol Strategies Inc.

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: